Before presenting my ASH summary, I’ll mention a late-breaking abstract presentation that I attended this morning. Maybe you’ve already heard about CAR-T therapy (Chimeric Antigen Receptor for T-cells). This very new immunology treatment removes T-cells from the patient and re-engineers and re-infuses them in the patient, so that these CAR-T cells recognize and destroy cancer […]
- All Good Things Must Come to an EndAll good things must come to an end as they [...]
- Last Few Hours at ASHThere are only a few abstracts left to attend and [...]
- News about Myeloma Treatment Advances Has Been HearteningWell I survived the first day and half here at [...]
- Looking Ahead to ASH 2015As I prepare to attend ASH for a second time [...]
- Myeloma Highlights from ASH 2015 ConferenceThis is my tenth year attending ASH (American Society of [...]
- Vampire ConventionVampire Convention I explained to my daughter that I was [...]
- My Favorite Moment at ASH 2015I thoroughly enjoyed hearing Dr. Brian Durie’s abstract presentation on [...]
- 20 years post-diagnosis, I am more hopeful than ever for the future of the myeloma family!!What a year it has been for the myeloma community. [...]
- "John, nice post. Thanks for reminding me about the"
- "Good job Jim! Thanks for the long hours to get im"
- "Very well said, Jim. Thank you so much IMFHughMYE"
ASPIRE
bortezomib
BSRI
clinical trial
daratumumab
darzalex
elotuzamab
elotuzumab
FDA
GMAN
Hematological Malignancies
high risk smoldering
immunotheraphy
IMWG
ixazomib
lenalidomide
Mike Katz
monoclonal antibodies
MRD
neoplasia
Next generation flow
NGF
ninlaro
ODAC
panobinostat
phamis
revlimid
smoldering
stem cell transplant
VRD
-
Archives
-
Meta